Table 1 Content of Review Series "Epi-Drugs: from chemistry via biology to medicine and back"

I. General introduction to epigenetic drugs and ongoing actions

1. A short general statement to introduce this series of reviews

2. An overview of EPICHEMBIO COST action

II. Old targets, new drugs

3. DNMT inhibitors

4. HDAC inhibitors

5. SirT modulators

III. Novel epigenetic targets and new drugs

6. HAT inhibitors

7. BRD hitting drugs

8. Histone methyltransferases and demethylases

9. EZH2

10. LSD

11. Multi-Target epidrugs

IV. Status of animal studies, potential clinical applications/current trials

12. Oncology, solid cancers Prostate

13. Onco-Hematological

14. The case of MM

15. Metabolic dysregulations

16. Neurodegenerations/ageing

17. Regenerative Medicine

VI. Where to take it from here: (off)target identification and validation approaches

18. Studying epigenetic complexes and their inhibitors with the proteomics toolbox

19. Epigenetic assays for chemical biology and drug discovery

20. New technologies basic/clinical epigenomics